Phase I Open-Label Single-Arm Study of BCMA/CD19 Dual-Targeting FasTCAR-T Cells (GC012F) As First-Line Therapy for Transplant-Eligible Newly Diagnosed High-Risk Multiple Myeloma

被引：16

作者：

Du, Juan ^{[1
]}

Fu, Weijun ^{[2
]}

Lu, Jing ^{[2
]}

Qiang, Wanting ^{[2
]}

He, Haiyan ^{[2
]}

Liu, Jin ^{[2
]}

Yang, Ying ^{[2
]}

Feng, Zhongyuan ^{[2
]}

Jin, Lina ^{[2
]}

Fan, Xiaoqiang ^{[2
]}

Liu, Jia ^{[3
]}

Zhang, Qi ^{[3
]}

Shen, Lianjun ^{[3
]}

Weng, Lihong ^{[3
]}

Cao, Wei ^{[3
]}

机构：

[1] Second Mil Med Univ, Shanghai Changzheng Hosp, Myeloma & Lymphoma Ctr, Dept Hematol, Shanghai, Peoples R China

[2] Naval Med Univ, Changzheng Hosp, Myeloma & Lymphoma Ctr, Dept Hematol, Shanghai, Peoples R China

[3] Gracell Biotechnol Ltd, Shanghai, Peoples R China

来源：

关键词：

D O I：

10.1182/blood-2022-162295

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：2